Recent clinical trial results indicate that also breast cancer patients with HER2-low expressing cancers would benefit from trastuzumab (together with deruxtecan (T-Dxd)) treatment, with significantly improved progression-free survival and overall survival. The gene discussed is ERBB2; the disease is breast cancer.